Mallinckrodt Institute of Radiology, Washington University, Saint Louis, Missouri, USA.
Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.
J Magn Reson Imaging. 2017 Aug;46(2):338-353. doi: 10.1002/jmri.25625. Epub 2017 Jan 13.
Gadolinium-based contrast agents (GBCAs) have been used in magnetic resonance imaging (MRI) since the 1980s and are now administered in up to 35% of all MRI examinations. While GBCAs were initially felt to carry minimal risk, the subsequent identification of GBCAs as the key etiologic factor in the development of nephrogenic systemic fibrosis (NSF) has raised concerns about the broader health impacts of gadolinium exposure. Clinicians, radiologists, and patients should be aware of the most up-to-date data pertaining to the risks of GBCA administration. Specific issues covered in this review article include immediate adverse reactions; pregnancy and lactation; and gadolinium deposition and toxicity, with a special focus on NSF. Practice recommendations based on the presented data, as well as current professional society guidelines, are provided for each section.
1 Technical Efficacy: Stage 5 J. MAGN. RESON. IMAGING 2017;46:338-353.
自 20 世纪 80 年代以来，钆基造影剂（GBCAs）已应用于磁共振成像（MRI）中，目前在多达 35%的所有 MRI 检查中使用。虽然最初认为 GBCAs 风险极小，但随后发现 GBCAs 是导致肾源性系统性纤维化（NSF）发展的关键病因因素，这引起了人们对接触钆暴露的更广泛健康影响的关注。临床医生、放射科医生和患者应了解与 GBCA 给药相关的最新风险数据。本文综述涵盖了以下几个方面：即刻不良反应；妊娠和哺乳期；以及钆沉积和毒性，特别关注 NSF。针对每个部分，根据提供的数据以及当前专业学会指南，给出了实践建议。
1 技术效果：5 级 J. MAGN. RESON. IMAGING 2017；46：338-353。
